Combinostics today announced that the company has been selected for the MassChallenge HealthTech 2019 program in Boston. MassChallenge is a global network of zero-equity startup accelerators. Combinostics was selected for the Boston program by a pool of institutions, providers, and payors looking to form unique partnerships and solve challenges with digital health startups. More information about the program and participating companies is found at https://masschallenge.org/media/MassChallenge-HealthTech-Announces-2019-Cohort-Top-Digital-Health-Startups.
Lennart Thurfjell, CEO of Combinostics commented: “Being selected for the MassChallenge HealthTech program fits very well with our plans to enter the US market. Working with healthcare partners in the program will help us accelerate our presence on this important market”.
Combinostics is a Finnish digital health company that develops and markets advanced tools for data-driven diagnostics. The technology is generic and can be applied to any disease area but Combinostics’ first application concerns early detection and differential diagnostics in Alzheimer’s disease and other dementias. Combinostics’ cNeuro® platform includes cMRI for quantification of MRI brain scans and cDSI for data-driven clinical decision support in dementia. cNeuro cMRI and cDSI have been certified according to the European Medical Device Directive (93/42/EEC). cNeuro cMRI is FDA 510(k) cleared and cDSI is excluded from the definition of a device in the US based on section 520(o)(1)(E) of the FD&C Act.